The committed equity facilities, which will provide total committed equity capital financing of up to $142.5 million in the aggregate to public companies, include:
- A $75-million committed equity financing facility to Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a company that focuses on repurposed drugs for central nervous system conditions;
- A $25-million committed equity financing facility to Plus Therapeutics, Inc. (NASDAQ: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes;
- A $20-million committed equity financing facility to TEN Holdings, Inc. (NASDAQ: HXLD), a company that provides event planning, production, and broadcasting services, specializing in virtual, hybrid, and physical events;
- A $12.5-million committed equity financing facility to Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes; and
- A $10-million committed equity financing facility to Aqua Metals Inc. (NASDAQ: AQMS), a company engaged in the business of recycling lead through a novel, proprietary and patent-pending process that it developed.
Partner Anthony Marsico in New York led the Reed Smith capital markets team on each of these transactions. He was assisted by associates Marisa Rametta, Lan Deng and Madison Old.
About Reed Smith
Reed Smith is a dynamic international law firm dedicated to helping clients move their businesses forward. With an inclusive culture and innovative mindset, we deliver smarter, more creative legal services that drive better outcomes for our clients. Our deep industry knowledge, long-standing relationships and collaborative structure make us the go-to partner for complex disputes, transactions and regulatory matters.
For more information, please visit reedsmith.com.
